Project Grant R01HL183586
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $851K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $834,899 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify inflammatory biosignatures that distinguish pain phenotypes in sickle cell disease. The research, titled "Inflammatory Biosignatures for the Identification of Sickle Cell Associated Pain Phenotypes (IBIS-CAP)," develops proteomic signatures composed of multiple biomarkers to characterize...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $873,801 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epithelial reprogramming mechanisms that distinguish normal regenerative repair from pathologic fibrotic remodeling in chronic lung diseases, particularly idiopathic pulmonary fibrosis. The research examines how airway and alveolar epithelial stem and progenitor cells progress through intermediate...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $1.669 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for data-consistent motion-correction reconstruction of PET/MR imaging targeting coronary atherosclerotic plaque activity. The research addresses motion artifacts that degrade spatial resolution and quantitative accuracy in coronary PET imaging, particularly for low-count tracers such as 68GA-DOTATATE....
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $570,666 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a streamlined base editor reengineering platform that enhances gene editing specificity and selectivity for therapeutic applications. The recipient will establish an engineering platform to accelerate base editor development by integrating a naturally occurring...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $462,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct comparative analysis of thrombogenic risk across menopausal stages in women with HIV. The research examines sex-based differences in cardiovascular disease risk among women with HIV, focusing on how immune activation, platelet reactivity, and age-related changes in sex hormones interact to elevate...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded Icahn School of Medicine at Mount Sinai $809,307 on July 1, 2026, for a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL183991). The award funds population-based genomic screening for transthyretin amyloidosis (ATTRV), a treatable cardiovascular and neuropathic condition caused by mutations in the TTR gene that disproportionately affects African American and...